Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 known ✓ | P00918 | 2/20 | 0.56 |
| ▸ | GAA known ✓ | P10253 | 1/20 | 0.53 |
| ▸ | SCN1A known ✓ | P35498 | 1/20 | 0.53 |
| ▸ | SCN2A known ✓ | Q99250 | 1/20 | 0.53 |
| ▸ | SCN3A known ✓ | Q9NY46 | 1/20 | 0.53 |
| ▸ | HDAC4 known ✓ | P56524 | 3/20 | 0.52 |
| ▸ | HDAC1 known ✓ | Q13547 | 3/20 | 0.52 |
| ▸ | HDAC7 known ✓ | Q8WUI4 | 3/20 | 0.52 |
| ▸ | HDAC11 known ✓ | Q96DB2 | 3/20 | 0.52 |
| ▸ | HDAC8 known ✓ | Q9BY41 | 3/20 | 0.52 |
| ▸ | HDAC6 known ✓ | Q9UBN7 | 3/20 | 0.52 |
| ▸ | HDAC9 known ✓ | Q9UKV0 | 3/20 | 0.52 |
| ▸ | HDAC5 known ✓ | Q9UQL6 | 3/20 | 0.52 |
| ▸ | HDAC3 known ✓ | O15379 | 2/20 | 0.52 |
| ▸ | HDAC2 known ✓ | Q92769 | 2/20 | 0.52 |
| ▸ | HDAC10 known ✓ | Q969S8 | 2/20 | 0.52 |
| ▸ | EGFR known ✓ | P00533 | 1/20 | 0.52 |
| ▸ | KCNH2 known ✓ | Q12809 | 1/20 | 0.52 |
| ▸ | LTA4H | P09960 | 2/20 | 0.62 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.60 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL188327 | 0.98 | LTA4H (0.64) | LTA4HL3MBTL1EPHX2KDM1AMAPT | |
| Bromide SCHEMBL11434219 | 0.96 | LTA4H (0.62) | LTA4HL3MBTL1EPHX2KDM1AMAPT | |
| Nitrogen SCHEMBL28401399 | 0.94 | LTA4H (0.60) | LTA4HL3MBTL1EPHX2KDM1AMAPT | |
| Hydrochloric Acid SCHEMBL19747848 | 0.85 | CA1 (0.67) | MAPTCA1CA2GAAMEN1 | |
| Hydrochloric Acid SCHEMBL12477633 | 0.85 | L3MBTL1 (0.69) | LTA4HL3MBTL1EPHX2KDM1AMAPT | |
| SCHEMBL11573347 | 0.84 | TERT (0.58) | LTA4HL3MBTL1EPHX2KDM1AMAPT | |
| Dimethylformamide SCHEMBL27730038 | 0.84 | LTA4H (0.51) | LTA4HL3MBTL1EPHX2KDM1AMAPT | |
| SCHEMBL9001585 | 0.83 | KDM1A (0.59) | LTA4HL3MBTL1EPHX2KDM1AMAPT | |
| SCHEMBL11789125 | 0.83 | ALDH1A1 (0.70) | LTA4HL3MBTL1MAPTCA1CA2 | |
| SCHEMBL11644079 | 0.83 | NPC1 (0.61) | LTA4HL3MBTL1MAPTCA1CA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 101 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-119874677-B | Imidazolidinone compound, porous organic polymer gel, and preparation methods and applications thereof | 四川大学 | 2025-06-13 | — | — | CN | claimed |
| CN-119874677-A | Imidazolidinone compound, porous organic polymer gel, and preparation methods and applications thereof | 四川大学 | 2025-04-25 | — | — | CN | claimed |
| CN-210826000-U | M-amino acetanilide hydrochloride mother liquor recycling and applying device with nitrogen protection | 九江富达实业有限公司 | 2020-06-23 | — | — | CN | claimed |
| US-12492199-B2 | Pyridopyrimidines as histamine H4-receptor inhibitors | FAES FARMA, S.A. (ES) | 2025-12-09 | — | — | US | disclosed |
| CN-119874677-B | Imidazolidinone compound, porous organic polymer gel, and preparation methods and applications thereof | 四川大学 | 2025-06-13 | — | — | CN | disclosed |
| CN-119874677-A | Imidazolidinone compound, porous organic polymer gel, and preparation methods and applications thereof | 四川大学 | 2025-04-25 | — | — | CN | disclosed |
| US-20240083857-A1 | 2-Methyl-Quinazolines | Bayer Pharma AG (DE) | 2024-03-14 | — | — | US | disclosed |
| WO-2024036317-A1 | METHODS FOR LABELING N-TERMINAL GLYCINE FOR PROTEOMICS | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2024-02-15 | — | — | WO | disclosed |
| CN-112739699-B | Pyridopyrimidine compounds as histamine H4 receptor inhibitors | 费斯制药股份有限公司 | 2023-11-28 | — | — | CN | disclosed |
| CN-115896222-A | Enzymatic preparation method of cefalexin | 河南康达制药有限公司 | 2023-04-04 | — | — | CN | disclosed |
| EP-3827005-B1 | PYRIDOPYRIMIDINES AS HISTAMINE H4-RECEPTOR INHIBITORS | FAES FARMA SA (ES) | 2022-08-17 | — | — | EP | disclosed |
| US-5306826-A | Mixing mixture of Schiff bases of amides or amides and aldehyde, solvent, optically active acid, water to form salt, separating diastereomers, converting salt to amide | STAMICARBON B.V. (NL) | 1994-04-26 | — | — | US | disclosed |
| EP-0431121-A1 | PROCESS FOR THE RESOLUTION OF THREO-3-[(2-AMINOPHENYL)-THIO]-2-HYDROXY-3-(4-METHOXY-PHENYL)PROPIONIC ACID. | RICHTER GEDEON VEGYESZET (HU) | 1991-06-12 | — | — | EP | disclosed |
| EP-0371332-A1 | Reactive dyes | BAYER AG (DE) | 1990-06-06 | — | — | EP | disclosed |
| US-4761416-A | ENZYME INHIBITORS, INOTROPIC AGENTS | SYNTEX (U.S.A.) INC. (US) | 1988-08-02 | — | — | US | disclosed |
| US-4739056-A | ENZYME INHIBITORS | SYNTEX (U.S.A.) INC. (US) | 1988-04-19 | — | — | US | disclosed |
| EP-0254327-A2 | N-N-disubstituted-omega-(2-amino-3-(carbonylmethyl)-3,4-dihydroquinazolinyl) oxyalkylamides and related compounds | SYNTEX (U.S.A.) INC. (US) | 1988-01-27 | — | — | EP | disclosed |
| US-4402958-A | ANXIOLYTIC AGENTS | AMERICAN CYANAMID COMPANY (US) | 1983-09-06 | — | — | US | disclosed |
| US-4169106-A | Antiarrhythmic N,N'-bis(phenylcarbamoylalkyl)amidines | COOPER LABORATORIES, INC. (US) | 1979-09-25 | — | — | US | disclosed |
| US-4036852-A | Optical resolution of phenyl-glycine amide | STAMICARBON B.V. (NL) | 1977-07-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240083857-A1 | 2-Methyl-Quinazolines | NRAS, KRAS, KSR2 | CA2 3422/4885GAA 2765/4885SCN1A 3594/4885 |
| US-12492199-B2 | Pyridopyrimidines as histamine H4-receptor inhibitors | HRH4, HRH2, HRH3 | CA2 1722/4885GAA 2480/4885SCN1A 1150/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.